People have to have thoroughly recovered from your acute harmful consequences of all prior anti-most cancers therapy and need to fulfill the following bare minimum period from prior anti-cancer directed therapy just before enrollment. Experimental: Dose expansion_sub-population 2_lower dose of niraparib MTDs and/or candidate RP2Ds for elimusertib used in combination https://kuwanon-a01100.blogerus.com/49287526/a-review-of-gsmtx4-tfa-1209500-46-8-free-base